Your browser is no longer supported. Please, upgrade your browser.
Simulations Plus, Inc.
Index- P/E139.59 EPS (ttm)0.51 Insider Own23.20% Shs Outstand19.93M Perf Week-13.52%
Market Cap1.46B Forward P/E105.16 EPS next Y0.68 Insider Trans-2.32% Shs Float15.29M Perf Month18.61%
Income9.80M PEG9.31 EPS next Q0.14 Inst Own64.80% Short Float10.28% Perf Quarter-0.99%
Sales42.90M P/S33.94 EPS this Y5.90% Inst Trans0.75% Short Ratio7.48 Perf Half Y15.12%
Book/sh7.93 P/B8.98 EPS next Y19.40% ROA8.70% Target Price87.75 Perf Year113.98%
Cash/sh5.81 P/C12.25 EPS next 5Y15.00% ROE9.70% 52W Range26.00 - 83.78 Perf YTD-1.02%
Dividend0.24 P/FCF165.44 EPS past 5Y17.40% ROI6.00% 52W High-15.03% Beta-0.02
Dividend %0.34% Quick Ratio24.00 Sales past 5Y17.80% Gross Margin75.70% 52W Low173.81% ATR3.52
Employees129 Current Ratio24.00 Sales Q/Q13.80% Oper. Margin26.90% RSI (14)50.87 Volatility6.10% 4.64%
OptionableYes Debt/Eq0.00 EPS Q/Q6.00% Profit Margin22.70% Rel Volume1.00 Prev Close72.91
ShortableYes LT Debt/Eq0.00 EarningsJan 11 AMC Payout45.20% Avg Volume210.17K Price71.19
Recom1.70 SMA20-1.64% SMA507.71% SMA20020.61% Volume209,615 Change-2.36%
Jan-12-21Downgrade Craig Hallum Buy → Hold
Oct-16-20Initiated Raymond James Outperform $95
Sep-08-20Initiated Oppenheimer Outperform $79
Jan-06-20Initiated Craig Hallum Buy $40
Jan-14-21 08:30AM  
Jan-13-21 11:15AM  
Jan-12-21 12:57PM  
Jan-11-21 09:00PM  
Jan-08-21 10:07AM  
Jan-07-21 04:10PM  
Jan-06-21 10:51AM  
Jan-05-21 04:55PM  
Jan-04-21 08:30AM  
Dec-25-20 04:32AM  
Dec-21-20 09:45AM  
Dec-16-20 08:30AM  
Dec-10-20 06:47PM  
Dec-03-20 08:30AM  
Dec-01-20 04:05PM  
Nov-17-20 10:47AM  
Nov-16-20 10:00PM  
Nov-10-20 08:30AM  
Nov-09-20 08:30AM  
Nov-05-20 08:30AM  
Nov-04-20 12:30PM  
Nov-03-20 08:30AM  
Oct-27-20 08:30AM  
Oct-21-20 11:40AM  
Oct-20-20 03:53PM  
Oct-13-20 08:30AM  
Oct-09-20 01:12PM  
Sep-29-20 08:30AM  
Sep-22-20 08:30AM  
Sep-15-20 08:30AM  
Sep-14-20 09:38AM  
Sep-03-20 01:30PM  
Sep-02-20 08:30AM  
Aug-31-20 05:00PM  
Aug-24-20 01:48AM  
Aug-10-20 04:01PM  
Aug-05-20 10:28PM  
Aug-04-20 12:07PM  
Jul-10-20 10:30AM  
Jul-09-20 09:30PM  
Jul-05-20 10:52PM  
Jul-02-20 08:30AM  
Jul-01-20 12:30PM  
Jun-11-20 12:37PM  
May-28-20 08:30AM  
May-27-20 05:48PM  
May-21-20 08:30AM  
May-15-20 10:11AM  
May-13-20 08:30AM  
May-06-20 08:30AM  
Apr-21-20 01:24PM  
Apr-17-20 06:00AM  
Apr-10-20 09:17AM  
Apr-09-20 05:55PM  
Apr-07-20 08:30AM  
Apr-02-20 04:15PM  
Mar-30-20 11:07AM  
Mar-26-20 01:46PM  
Mar-18-20 08:30AM  
Mar-05-20 10:57AM  
Feb-26-20 09:56AM  
Feb-04-20 08:30AM  
Jan-13-20 04:22PM  
Jan-12-20 09:48AM  
Jan-10-20 10:15AM  
Jan-09-20 05:25PM  
Jan-03-20 08:30AM  
Jan-01-20 12:30PM  
Dec-13-19 10:47AM  
Dec-09-19 09:15AM  
Dec-05-19 08:30AM  
Nov-29-19 08:04AM  
Nov-21-19 08:30AM  
Nov-14-19 08:30AM  
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WOLTOSZ WALTER SDirectorDec 23Sale72.7124,0001,745,0404,659,614Dec 23 06:22 PM
OCONNOR SHAWNChief Executive OfficerNov 30Sale56.506,381360,5270Nov 30 06:31 PM
Ralph David L.DirectorNov 30Sale55.655,000278,24316,581Dec 02 04:10 PM
OCONNOR SHAWNChief Executive OfficerNov 23Sale56.255,500309,3596,381Nov 25 01:07 PM
OCONNOR SHAWNChief Executive OfficerNov 20Option Exercise23.7520,000475,00011,881Nov 23 05:53 PM
WOLTOSZ WALTER SDirectorOct 27Sale68.9524,0001,654,8004,707,359Oct 27 04:44 PM
WOLTOSZ WALTER SDirectorSep 24Sale66.0824,0001,585,9204,731,359Sep 24 06:24 PM
WOLTOSZ WALTER SDirectorJul 27Sale66.1324,0001,587,1204,779,153Jul 28 04:35 PM
WOLTOSZ WALTER SDirectorJun 24Sale55.8224,0001,339,6804,803,153Jun 24 09:53 PM
WOLTOSZ WALTER SDirectorMay 22Sale39.3524,000944,4004,827,153May 26 05:36 PM
WOLTOSZ WALTER SDirectorApr 24Sale41.2524,000990,0004,850,772Apr 27 05:08 PM
WOLTOSZ WALTER SDirectorMar 25Sale31.7124,000761,0404,874,772Mar 26 06:42 PM
WOLTOSZ WALTER SDirectorFeb 24Sale36.6924,000880,5604,898,772Feb 26 04:48 PM
WOLTOSZ WALTER SDirectorJan 27Sale33.2624,000798,2404,922,327Jan 28 09:15 PM